Equities

Kohjin Bio Co Ltd

177A:TYO

Kohjin Bio Co Ltd

Actions
  • Price (JPY)1,777.00
  • Today's Change73.00 / 4.28%
  • Shares traded45.40k
  • 1 Year change--
  • Beta--
Data delayed at least 20 minutes, as of May 31 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Kohjin Bio Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of bacterial testing media, in vitro diagnostic drugs, cell culture media, as well as contract cell processing. The Company operates through three segments. The Tissue Culture business segment develops, manufactures, and sells tissue culture media, including serum-free media used for research purposes in regenerative medicine and immunotherapy. The Microbiology business segment develops, manufactures, and sells a wide variety of microorganism detection media used for pathogen testing in the clinical and food fields, and quality testing in various fields such as pharmaceuticals and cosmetics. The Cell Processing business segment conducts cell processing operations under contract from medical institutions at facilities that have obtained permission to manufacture specified cell products based on the Regenerative Medicine Safety Act.

  • Revenue in JPY (TTM)4.77bn
  • Net income in JPY384.98m
  • Incorporated1981
  • Employees157.00
  • Location
    Kohjin Bio Co Ltd5-1-3, ChiyodaSAKADO-SHI 350-0214JapanJPN
  • Phone+81 492843781
  • Fax+81 492844784
  • Websitehttps://kohjin-bio.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Symbio Pharmaceuticals Ltd4.64bn-2.74bn7.07bn109.00--0.9848--1.52-66.88-66.88113.80156.380.54392.765.1442,594,130.00-32.15-19.18-35.33-23.6278.3865.84-59.12-24.3210.43--0.00---44.157.82-266.45--42.39--
MEDRx Co Ltd22.57m-770.66m7.08bn22.00--3.37--313.46-20.97-20.970.612847.840.01430.004.221,025,955.00-48.80-58.15-50.27-62.23100.0095.70-3,414.38-1,526.1743.57--0.00---50.3528.6016.04---55.29--
Carna Biosciences, Inc.1.58bn-1.03bn7.19bn67.00--1.94--4.55-60.32-60.3292.24205.190.35741.2412.6323,578,990.00-23.36-14.45-25.26-16.9589.0390.59-65.36-35.4213.18--0.0326--17.2416.5914.57---27.69--
Veritas In Silico Inc-100.00bn-100.00bn7.47bn15.00--3.17----------363.52------------------------40.94--0.00--101.54--123.38------
K Pharma Inc500.00m-221.98m8.20bn15.00--2.86--16.41-18.94-18.9443.04247.430.20954.49--33,333,330.00-9.30---9.83--91.00---44.40--42.60--0.00------166.34------
TMS Co Ltd0.00-960.04m8.46bn14.00--2.45-----25.89-25.890.0085.770.00----0.00-26.14---26.78-------------2,219.420.00-------11.51------
CellSeed Inc193.68m-892.21m8.54bn35.00--4.00--44.12-29.71-29.716.4764.750.0881.637.625,533,600.00-40.53-49.69-43.83-54.5556.5863.66-460.67-428.6219.14--0.0669--50.39-28.62-11.43--80.73--
Wakamoto Pharmaceutical Co Ltd7.74bn108.96m8.85bn292.0080.910.73390.511.143.143.14222.97346.510.49712.092.57--0.70-2.280.8046-2.6446.5251.001.41-3.973.85--0.0083---10.65-6.35-21.19--4.93--
Tsubota Laboratory Inc673.53m-641.32m9.08bn10.00--6.64--13.48-25.15-25.1526.4253.450.27112.0437.74---25.82---36.41--3.17---95.22--2.31-489.860.0788---29.45---811.14------
Kohjin Bio Co Ltd4.77bn384.98m9.08bn157.0023.152.6722.281.9076.7776.77951.17666.48----------------39.44--8.07--1.14--0.4249--0.5715---53.61------
CanBas Co Ltd (Parent)0.00-1.09bn9.17bn12.00--3.06-----64.47-64.470.00166.100.00----0.00-43.91-65.86-45.99-79.11-------1,094.10----0.00-------45.41------
Linical Co Ltd12.31bn338.27m9.87bn759.0026.641.0911.520.80214.9814.98544.93364.600.6837--3.59--1.884.013.156.3330.7030.992.755.48----0.260350.10-1.671.70-66.32-9.86-10.184.56
Stella Pharma Corp269.49m-763.75m10.46bn46.00--4.40--38.82-24.63-24.638.7076.120.06610.05083.98---18.74-22.50-21.00-24.8380.63---283.40-488.655.52-379.390.2819--17.65--1.94---5.87--
AnGes Inc249.94m-6.35bn10.53bn145.00--0.3696--42.14-32.62-32.621.29124.450.00770.08624.771,723,752.00-19.47-28.50-23.06-33.1439.8539.42-2,540.59-6,726.820.9124--0.0139--128.13-24.1749.45--12.11--
KOEI CHEMICAL COMPANY, LIMITED19.43bn299.18m11.21bn387.0037.410.51294.800.577161.1761.173,971.904,460.940.49571.663.80--0.76593.150.9973.9427.1725.241.555.850.6907115.660.320743.884.441.19-56.72-20.82-3.2910.76
Data as of May 31 2024. Currency figures normalised to Kohjin Bio Co Ltd's reporting currency: Japanese Yen JPY
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.